Industry funding of CME: the times they are a-changing?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1654, 2008-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EMEA: For Patients or For Industry?

By Garattini Silvio

PharmacoEconomics, Vol. 23, Iss. 3, 2005-01 ,pp. : 207-208

Adis International

Access to resources Recommend Favorite

Prioritizing Comparative Effectiveness Research: Are Drug and Implementation Trials Equally Worth Funding?

By Gandjour Afschin

PharmacoEconomics, Vol. 29, Iss. 7, 2011-07 ,pp. : 555-561

Adis International

Access to resources Recommend Favorite

Does the Funding Source Influence the Results in Economic Evaluations?: A Case Study in Bisphosphonates for the Treatment of Osteoporosis

By Fleurence Rachael L.

PharmacoEconomics, Vol. 28, Iss. 4, 2010-04 ,pp. : 295-306

Adis International

Access to resources Recommend Favorite

Tax hikes, budget squeezes cost of maintaining current NHS funding?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 584, 2009-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Could a patient-based formula guide funding allocation in the UK?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 643, 2011-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite